Global Professional Immune Cell Storage Market Strategic Research Report

Scope of the Report

The global Professional Immune Cell Storage market size is predicted to grow from US$ 1,071 million in 2025 to US$ 1,867 million in 2032; it is expected to grow at a CAGR of 8.3% from 2026 to 2032.

Professional immune cell storage entails the collection, isolation, testing, cryopreservation, and long-term storage of human-derived immune cells, alongside the provision of supporting services—such as thawing, release, and cryogenic transport—when required for subsequent medical, scientific research, or drug development purposes. The service workflow typically encompasses sample collection coordination, sample transport, cell isolation and enrichment, assessment of cell count and viability, immunophenotyping, controlled-rate cooling, deep-cryogenic storage in liquid nitrogen, digital sample management, and retrieval for thawing.

The growth of the professional immune cell storage market is primarily driven by the continued expansion of the cell and gene therapy industry, an increase in clinical programs for tumor immunotherapies, rising R&D investment in biopharmaceuticals, and growing demand for high-quality starting materials. As CAR-T, TCR-T, CAR-NK and other immune cell therapies continue to enter the clinical development and commercialization stages, hospitals, cell therapy companies, pharmaceutical companies and research institutions have an increasing demand for standardized processing, long-term preservation, quality tracking and rapid retrieval of PBMCs, T cells, NK cells and leukocyte apheresis products. At the same time, the increased acceptance in some markets of preserving relatively young immune cells during healthy periods has also driven the development of personal pre-stored products. Advances in technologies such as automated cell separation, controlled-rate freezing, liquid nitrogen vapor-phase storage, digital sample management, real-time temperature monitoring, and cryogenic logistics have further improved cell cryopreservation quality, post-thaw viability, and end-to-end traceability. However, uncertainties regarding the future clinical utility of stored cells, variations in regulatory and quality standards across countries, and the high costs associated with establishing and operating professional cell banks continue to constrain the pace of industry-wide adoption.

This report presents a comprehensive overview of the global Professional Immune Cell Storage market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Natural Killer Cell Banking
• T-Cell Banking
• Others

Segment by Storage Duration

• Short-term Storage
• Medium-term Storage
• Long-term Personal Storage

Segment by players, this report covers

• Shanghai Cell Therapy Group
• Boyalife
• Vcanbio
• Health & Biotech
• HealthBanks
• Origincell
• Shenzhen Beike Bio-Technology
• CryoCord
• Sino Biotech
• Qilu Cell Therapy
• Haier International Cell Bank
• Guangdong Saier Biotechnology
• Yuanpin Cell Biotechnology Group
• CytoMed Therapeutics
• Bioscience Institute
• CellEntrust
• Immunaeon
• Guangzhou SALIAI Stemcell
• S-Evans Biosciences

Segment by Application

• Personal
• Clinical
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Professional Immune Cell Storage market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Personal, Clinical, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact